Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8%

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 10,750,000 shares, a growth of 5.8% from the December 15th total of 10,160,000 shares. Based on an average daily trading volume, of 824,600 shares, the short-interest ratio is presently 13.0 days. Currently, 19.8% of the company's stock are sold short.

Structure Therapeutics Stock Performance

NASDAQ:GPCR traded up $0.08 during trading on Friday, reaching $27.06. The company's stock had a trading volume of 846,835 shares, compared to its average volume of 770,004. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -36.57 and a beta of -2.78. Structure Therapeutics has a 12 month low of $23.50 and a 12 month high of $62.74. The firm has a 50 day moving average of $30.78 and a 200-day moving average of $36.03.

Institutional Trading of Structure Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Sandia Investment Management LP bought a new position in shares of Structure Therapeutics during the 2nd quarter valued at approximately $39,000. GAMMA Investing LLC grew its holdings in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares during the period. Assetmark Inc. increased its position in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after buying an additional 719 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics in the fourth quarter valued at $40,000. Finally, Quarry LP purchased a new position in shares of Structure Therapeutics during the 2nd quarter valued at $79,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GPCR. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an "overweight" rating and a $118.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price on the stock. JMP Securities reissued a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.